As of 2020, Merck & Co.’s Keytruda (also known as Pembrolizumab) has been approved for use in metastatic mesothelioma patients to diminish tumour volume, but only if they have certain specific genetic markers. It is most effective when it’s used in combination with other therapies, but even then its effect is moderate at best.
Many law students reach the end of their degree before realising they don’t want to follow the typical career trajectory of a barrister or a solicitor – but that certainly doesn’t mean their time was wasted.
Lawyer Monthly is a news website and monthly legal publication with content that is entirely defined by the significant legal news from around the world.
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you consent to the use of cookies. Privacy PolicyOkI do not consent
